PULMONOGY / POST-COVID TREATMENT

• 

• 

• 

 

The goal, principle and scheme of the medical therapeutic experiment:

A medical therapeutic experiment is a multi-stage procedure aimed at applying an innovative method of treatment, technology or an innovative therapeutic preparation, which is not a standard therapy for a given illness. The medical therapeutic experiment is an alternative for patients who have not yet been treated or previous treatment has not produced the desired therapeutic effects. The main goal of the medical therapeutic experiment is to improve the patient’s health. The use of MSC therapy as part of a medical therapeutic experiment must always be supported by the consent of the Bioethical Commission at the District Medical Chamber in Częstochowa, Poland.

What are stem cells obtained from Wharton jelly?

Wharton’s jelly-derived mesenchymal stem cells – WJ-MSC are a population of multipotent stem cells, located in the umbilical cord, classified as gelatinous connective tissue.
Wharton jelly is made up mainly of mucopolysaccharides, including hyaluronic acid and chondroitin sulphate.
The mesenchymal stem cells used in the experiment have a fibroblast structure, show adhesion to plastic substrates and originate from unrelated and incompatible in the antigen range of tissue compliance and the main groups and Rh blood factor, donor.

Title of the medical therapeutic experiment:

“The use of mesenchymal cells obtained from Wharton’s jelly of an incompatible unrelated donor in the treatment of patients with idiopathic pulmonary fibrosis and patients with pulmonary fibrosis in whom there is no causal treatment and in which the applied treatment did not improve the clinical condition”.

General criteria for the selection of patients receiving therapy using WJ-MSC (Wharton’s jelly mesenchymal stem cells – Wharton jelly stem cells).

• patients of both sexes,
• age range: from 18 to 85,
• the obligation to use contraception during the course of therapy (applies to women).

• a signed report by an adult patient

• IPF diagnosis based on ATS-ERS guidelines

• specified or probable UIP (usual interstitial pneumonia) confirmed by SLB (surgical lung biopsy) by a pathologist or in the case of a negative HRCT biopsy with specific IPF features

Exclusion criteria from therapy:

• pregnancy and breast-feeding,
• diagnosis of other restrictive lung disease other than UIP or IPF
• severe or acute organ damage,
• an infectious disease, e.g. HIV, HBV, HCV, HPV,
• active infection requiring treatment,
• severe mental disorders,
• presence of malignant tumor,
• unstable state of the cardiovascular system,
• allergy to some antibiotics.

How can you qualify for MSC Therapy?

Patients are asked to send the following documents:

• complete medical documentation with a diagnosis of the disease,
• gasometry,
• spirometry and
• lung X-ray not older than 6 months
• Quality HCV RNA, borrelia IGG and IGM by western-blot, anti HBs, HIV
• Hepatitis B vaccination record

to the following address: komorki@cm-klara.pl or by post: Centrum Medyczne Klara, MSC Therapy, ul. Wał Dwernickiego 43/45, 42-202 Częstochowa, Poland where initial verification will take place.

After doctor qualification for MSC Therapy, Klara Medical Center acts on behalf of the Patient for the Bioethical Commission at the District Medical Chamber in Częstochowa, Poland.

At this stage, patients wait for the application to be reviewed by the Bioethical Commission.

In the case of a positively examined application, Klara Medical Center contacts the patient in order to provide information on:

• application dates
• the cost of therapy
• additional tests required
• organizational information

Diagram of a medical treatment experiment:

As part of the approval of the Bioethical Commission, the patient can receive up to 10 administrations of MSC. The duration of therapy is about 1.5 years.

• The interval between single administrations is 4-6 weeks – assessment of the treatment effect before each single injection.
• After the fifth administration of MSC, the patient starts a 6-month break, unless there are medical grounds for continuing therapy without taking into account the interruption.
• After the end of the 6-month interval, the therapy is resumed for a further 1-5 applications at intervals of 4-6 weeks or once every three months, if the patient’s condition has improved – assessment of the treatment effect before each single injection.
•  

Frequently Asked Questions:

• How long is the hospitalization at Klara Medical Center?

The patient spends 3 days in the hospital.
Day 1 – admission to the ward
Day 2 – administration of the MSC preparation
Day 3 – hospital discharge in the morning hours

• Can a parent / guardian or family member stay with the patient while in the hospital?

Yes, the cost in included.

If you would like to receive more information about stem cells treatment, please contact us at:

komorki@cm-klara.pl and / or +48 34 534 5003